BerGenBio

Regulatory Filings • Oct 16, 2023

Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting

Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting

BERGEN, Norway, October 16, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical needs, today announced that a poster and an oral

presentation summarizing completed studies with its lead product candidate

bemcentinib will be presented at the upcoming European Society of Clinical

Oncologists (ESMO) Annual Meeting 2023, to be held October 20-24 in Madrid.

Enriqueta Felip, M.D., Ph.D., Head of the Thoracic Cancer Unit at Vall d'Hebron

University Hospital, Spain will present the following poster summarizing the

final results from the BGBC008 Phase II study of bemcentinib in combination with

pembrolizumab in 2L NSCLC:

Poster Title: Final top-line results of the BGBC008 phase 2, multicenter study

of bemcentinib and pembrolizumab (bem+pembro) in 2nd line (2L) advanced non

-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571) of S

Session Date:  Onsite poster display date, Monday October 23

Poster Board Number: 1440P

The poster will be available on BerGenBio's website shortly following

presentation.

In addition, Dr. Oddbjorn Straume, M.D., Ph.D., Assistant Professor, Clinical

Science at the Haukeland University Hospital in Bergen, Norway will make an oral

presentation summarizing the results of the Investigator Led Study LBA52 with

bemcentinib in addition to pembrolizumab or dabrafenib/trametinib in 1L and 2L

metastatic melanoma patients:

Oral Presentation Title: A randomized Phase Ib/II study of the selective small

molecule AXL inhibitor bemcentinib in combination with either

dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma

Session Name:  LBA 52 "Melanoma and other skin tumors"

Session Date and Time: Saturday October 21, 15:50-15:55 CET

Location: Leon Auditorium, Hall 7

Martin Olin, Chief Executive Officer of BerGenBio, commented: "We are pleased to

share more data on bemcentinib which we believe substantiates our strategy to

focus on the treatment of Non-Small Cell Lung Cancer patients with a goal of

potentiating the effects of standard of care treatments.  We thank the patients

who participated in these studies, their families, and all participating

investigators as well as their clinical and nursing staff for contributing to

our understanding of bemcentinib as a potential cancer therapeutic."

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate, bemcentinib, a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visitwww.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.